In one study, extracellular alpha-synuclein treatment at nanomolar concentrations protected neurons against cellular stresses such as serum deprivation, oxidative stress, and excitotoxicity through the PI3/Akt signaling pathway[17]. BrdU-positive ndSHSY cells was decreased in alpha-synuclein-treated group compared with control group. Level of phosphorylated Akt in alpha-synuclein-treated group was higher compared with the control group. Our study demonstrates extracellular alpha-synuclein at nanomolar concentration benefits dopaminergic cell survivalviaAkt pathway. == Intro == Alpha-synuclein is definitely a principal component of Lewy body and Lewy neurites, which are pathologic hallmarks of Parkinson’s disease[1,2]. Alpha-synuclein is generally regarded as to play a role in synaptic activity[3], although its function remains mainly unfamiliar. Mutations in three loci (A53T, A30P, and E46K)[4,5,6] and multiplication[7,8] in the alpha-synuclein encoding gene have been recognized as causes of the inherited form of Parkinson’s disease. Consequently, it is proposed that alpha-synuclein contributes to the pathogenesis of Parkinson’s disease. Alpha-synuclein is definitely conventionally known as an intraneuronal protein. However, a series of studies demonstrated the presence of alpha-synuclein in extracellular fluids, probably as a result of the unconventional exocytosis of intravesicular alpha-synuclein[9]. The collected data suggest cytotoxic effects of the fibrillar aggregates[10,11] or the protofibrillar or oligomeric aggregates[12] of extracellular alpha-synuclein. In addition, it has been demonstrated that aggregated extracellular alpha-synuclein fibrils can be internalized in the cells and enhance the intracellular formation of protein inclusions, leading to cell death[13]. Consequently, extracellular alpha-synuclein has been indicated as a treatment target of Parkinson’s disease[14], and passive immunization for alpha-synuclein has recently Mouse monoclonal to NME1 been attempted[15,16]. Conversely, there is growing evidence suggesting that alpha-synuclein has also neuroprotective effects. In one study, extracellular alpha-synuclein treatment at Scoparone nanomolar concentrations safeguarded neurons against cellular stresses such as serum deprivation, oxidative stress, and excitotoxicity through the PI3/Akt signaling pathway[17]. Inside a transgenic mouse model, the improved manifestation of alpha-synuclein prevented paraquat-induced dopaminergic cell degeneration[18]. Endogenous alpha-synuclein induction by valproic acid showed protective effects against glutamate-induced excitotoxicity in rat cerebellar granule cells[19]. Wild-type alpha-synuclein rescued dopaminergic cells from both acute and chronic cytotoxicity induced by rotenone and maneb whereas mutant alpha-synuclein did not[20]. Thus far, it is uncertain as to whether alpha-synuclein takes on a Scoparone favorable part for neurons at physiologic concentrations, which are estimated to be from picomolar to nanomolar levels in cerebrospinal fluid[9,10]. In this study, we attempted to assess the effect of extracellular alpha-synuclein at nanomolar concentrations on neuronal survival in cultured dopaminergic cell lines. == RESULTS == == Effect of extracellular alpha-synuclein on cell viability in neuronally-differentiated SH-SY5Y (ndSHSY) cells == The effect of monomeric alpha-synuclein within the viability of undifferentiated SH-SY5Y (SHSY) cells and ndSHSY cells is definitely demonstrated inFigure 1. In ndSHSY cells, viability was improved when they were treated with alpha-synuclein for 24 hours at 50 nmol/L (from 100% to 126.8%,P< 0.001, data were presented while percentage of control) and at 100 nmol/L (from 100% to 120.2%,P= 0.001), while cell viability did not switch significantly in cells treated with 1 mol/L alpha-synuclein (P= 0.128). The switch in cell viability was not observed in alpha-synuclein-treated SHSY cells (Number 1). == Number 1. == Different effects of alpha-synuclein on cell viability in undifferentiated and neuronally-differentiated SH-SY5Y cells. Cell viability was not significantly improved in undifferentiated SH-SY5Y cells treated with alpha-synuclein (A) but significantly improved in neuronally-differentiated SH-SY5Y cells treated with nonomolar (50 and 100 nmol/L [M]) alpha-synuclein (B). Ideals are displayed as mean SD for three self-employed experiments.aP< 0.05,bP< 0.01,vs. control (CON) group (Mann-WhitneyUtest). == ndSHSY cell proliferation after alpha-synuclein treatment == Scoparone To see whether cell viability improved after alpha-synuclein treatment with increased cellular proliferation, cell proliferation was measured by determining the proportion of quantity of both 5-bromo-2-deoxyuridine (BrdU) and 4,6-diamidino-2-phenylindole (DAPI)-positive cells to quantity of DAPI-positive cells in 100-collapse microscopic filed (Numbers2,3). The.